Masimo Announces Vital Signs Check Application for the Root® Patient Monitoring and Connectivity Platform
July 09 2018 - 8:00AM
Business Wire
Masimo (NASDAQ: MASI) announced today the worldwide release
of the Vital Signs Check Application, an integrated patient data
collection and workflow application for the Masimo Root® patient
monitoring and connectivity platform. Vital Signs Check, available
for new and existing Root customers through a software upgrade,
augments Root’s versatility by helping to automate hospital vital
signs testing workflows.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20180709005223/en/
Masimo Root® Vital Signs Check (Photo:
Business Wire)
Root is a powerful, expandable platform that integrates an array
of technologies, devices, and systems to provide multimodal
monitoring and connectivity solutions – in a single,
clinician-centric hub. Root’s plug-and-play expansion capabilities
allow clinicians to simplify patient monitoring by bringing
together advanced rainbow SET™ Pulse CO-Oximetry, brain function
monitoring, regional oximetry, capnography, and vital signs
measurements on an easy-to-interpret, customizable display,
empowering clinicians with important information for making patient
assessments.
Root Vital Signs Check allows clinicians to streamline vital
signs measurement workflows and optimize patient data management
through:
- Automated patient association,
with the ability to quickly associate clinicians with their
measurement sessions and patients with their data using barcode
scanning or a drop-down menu that pulls data from a hospital’s HL7
Admit Discharge Transfer (ADT) system.
- Centralized data collection using a
single device. Root, with the use of its optional roll stand,
serves as a convenient, mobile data collection point for a variety
of integrated measurements, including oxygen saturation (SpO2),
pulse rate, respiration rate, noninvasive hemoglobin (SpHb®), and
noninvasive blood pressure and temperature (including, in the U.S.,
non-contact thermometry via the newly announced TIR-1™). Clinicians
can also enter up to 30 additional measurements for immediate
documentation and validation at the patient’s bedside, configured
for each care area’s protocols.
- Early Warning Scores.
Configurable early warning scores (EWS) can be calculated using up
to 14 Root-measured and manually-entered contributors, as
determined by hospital protocol.
- Immediate electronic charting at the
bedside, with the ability to send complete, comprehensive data
to the hospital electronic medical record (EMR) with the touch of a
button. If a network connection is interrupted or only available at
an access point, Root can store up to 1,000 sessions and
automatically push all data to the EMR once network access becomes
available, saving time and minimizing the need for manual
documentation. Local storage, coupled with unique patient
identifiers, also allows clinicians to trend and review progress
over time from the bedside, which may help to identify patterns of
deterioration.
Joe Kiani, Founder and CEO of Masimo, said, “From the operating
room to the emergency room, from the ICU to the med-surg unit, Root
is streamlining care, simplifying access to critical data, and
improving hospital workflows, all so that clinicians can stay
focused on their patients. With the Vital Signs Check app, Root’s
utility is further enhanced, taking an important aspect of hospital
care – the repetitive, data-and-labor-intensive measurement of
patient vitals – that can benefit greatly from automation and
bringing it in line with the best that modern technology
offers.”
@MasimoInnovates | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative
noninvasive monitoring technologies. Our mission is to improve
patient outcomes and reduce the cost of care. In 1995, the company
debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse
oximetry, which has been shown in multiple studies to significantly
reduce false alarms and accurately monitor for true alarms. Masimo
SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,1 improve CCHD screening in
newborns,2 and, when used for continuous monitoring with Masimo
Patient SafetyNet™* in post-surgical wards, reduce rapid response
activations and costs.3,4,5 Masimo SET® is estimated to be used on
more than 100 million patients in leading hospitals and other
healthcare settings around the world,6 and is the primary pulse
oximetry at 17 of the top 20 hospitals listed in the 2017-18 U.S.
News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo
introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total
hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®),
and more recently, Oxygen Reserve Index (ORi™), in addition to
SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo
introduced Root®, an intuitive patient monitoring and connectivity
platform with the Masimo Open Connect® (MOC-9®) interface, enabling
other companies to augment Root with new features and measurement
capabilities. Masimo is also taking an active leadership role in
mHealth with products such as the Radius-7® wearable patient
monitor, iSpO2® pulse oximeter for smartphones, and the MightySat™
fingertip pulse oximeter. Additional information about Masimo and
its products may be found at www.masimo.com. Published clinical
studies on Masimo products can be found at
http://www.masimo.com/evidence/featured-studies/feature/.
ORi has not received FDA 510(k) clearance and is not available
for sale in the United States.
*The use of the trademark Patient SafetyNet is under license
from University HealthSystem Consortium.
References
- Castillo A et al. Prevention of
Retinopathy of Prematurity in Preterm Infants through Changes in
Clinical Practice and SpO2 Technology. Acta Paediatr. 2011
Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of
pulse oximetry screening on the detection of duct dependent
congenital heart disease: a Swedish prospective screening study in
39,821 newborns. BMJ. 2009;Jan 8;338.
- Taenzer AH et al. Impact of Pulse
Oximetry Surveillance on Rescue Events and Intensive Care Unit
Transfers: A Before-And-After Concurrence Study. Anesthesiology.
2010; 112(2):282-287.
- Taenzer AH et al. Postoperative
Monitoring – The Dartmouth Experience. Anesthesia Patient Safety
Foundation Newsletter. Spring-Summer 2012.
- McGrath SP et al. Surveillance
Monitoring Management for General Care Units: Strategy, Design, and
Implementation. The Joint Commission Journal on Quality and Patient
Safety. 2016 Jul;42(7):293-302.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo Root®. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo Root, contribute to positive
clinical outcomes and patient safety; risks related to our belief
that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; as well as other
factors discussed in the "Risk Factors" section of our most recent
reports filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether
our expectations will prove correct. All forward-looking statements
included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these statements or the
"Risk Factors" contained in our most recent reports filed with the
SEC, whether as a result of new information, future events or
otherwise, except as may be required under the applicable
securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180709005223/en/
MasimoEvan Lamb, 949-396-3376elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024